Drozitumab clinical trials
Also written PRO95780.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses drozitumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PRO95780
- 5
Studies by the year they started
5 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Bevacizumab (2) · Folfox protocol (1) · Cetuximab (1) · FOLFIRI Regimen (1) · Irinotecan (1)
Studies
Open first, then newest update. How each study uses drozitumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)CompletedPhase 1Genentech, Inc.NCT00851136Written as PRO95780
- A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)TerminatedPhase 2Genentech, Inc.NCT00543712Written as PRO95780
- A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)CompletedPhase 2Genentech, Inc.NCT00517049Written as PRO95780
- A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)CompletedPhase 1Genentech, Inc.NCT00497497Written as PRO95780
- A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)CompletedPhase 2Genentech, Inc.NCT00480831Written as PRO95780
Codes
What other systems call drozitumab · ClinicalTrials.gg INT005606
- MeSH (NLM) C548876drozitumabOne source NLM
- UNII (FDA) SQ67484MA7DROZITUMABConfirmed FDA, NLM
- NCI Thesaurus C95784DrozitumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C548876 | drozitumab | One source NLM |
| UNII (FDA) | SQ67484MA7 | DROZITUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C95784 | Drozitumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.